___

• 1. Pavlakis N, Bell DR, Mill ward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291. 2. Qreen MR. Qemcitabine safety overview. Semin Oncol 1996; 23: S32-S35. 3. Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997. 4. flinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494-500.
• 5. Ay li, Buonannao F, Schaefer P, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. neurology 1998; 51: 1369- 1376. 6. Vaughn D, Jarvik J, Hackney D, et al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016. 7. Kontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527. 8. Delanty Pi, Vaughan C, Frucht S, Stubgen P. Erythropoetin-associated hypertensive posterior leukoencephalopathy. neurology 1997; 49: 686-689. 9. Klion AD, Kallesen J, Cowl CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586- 589. 10. Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cufuroxime-induced encephalopathy. neurology 1998; 50: 1873-1875. Il.Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A. Severe but reversible encephalopathy associated with cefepime. neurophysiol Clin 2000; 30: 383-386.